Hypoxia may enhance tumor cell resistance to chemotherapy, radiotherapy, and targeted therapies by modulating signaling pathways (e.g., PI3K/Akt, MAPK, and NF-κB) while altering the tumor microenvironment to reduce drug permeability or facilitate immune escape [218]. The gene discussed is NFKB1; the disease is neoplasm.